Optimal glucocorticoid therapy

Endocrine Development

Volumn 20, Issue , 2010, Pages 173-180

  Debono, Miguel ^a   Ross, Richard J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIINFLAMMATORY AGENT; CHRONOCORT; CORTISONE ACETATE; GLUCOCORTICOID; HYDROCORTISONE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ANDROGEN BLOOD LEVEL; ARTICLE; BEHAVIOR; BODY WEIGHT; CONGENITAL ADRENAL HYPERPLASIA; CONTINUOUS INFUSION; CORTICOSTEROID RELEASE; CORTICOSTEROID THERAPY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; METABOLIC DISORDER; MORTALITY; OSCILLATION; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATORY MECHANISM; SLEEP DISORDER; SUPRACHIASMATIC NUCLEUS;

ADRENAL INSUFFICIENCY; BODY WEIGHT; CALIBRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE;

EID: 78751563363     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000321241     Document Type: Article

References (25)

1. Krieger DT, Allen W, Rizzo F, Krieger HP: Characterization of the normal temporal pattern of plasma corticosteroid levels. J Clin Endocrinol Metab 1971;32:266-284.
2. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ: Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 2009;94:1548-1554.
3. Born J, Hansen K, Marshall L, Molle M, Fehm HL: Timing the end of nocturnal sleep. Nature 1999;397: 29-30.
4. Buckley TM, Schatzberg AF: On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab 2005;90:3106-3114.
5. Balsalobre A, Damiola F, Schibler U: A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 1998;93:929-937.
6. Balsalobre A, Brown SA, Marcacci L, Tronche F, Kellendonk C, Reichardt HM, Schutz G, Schibler U: Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science 2000;289:2344-2347.
7. Arendt J, Skene DJ: Melatonin as a chronobiotic. Sleep Med Rev 2000;9:25-39.
8. Derendorf H, Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M: Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 1991;31:473-476.
9. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ: Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2004;61:367-375.
10. Linder BL, Esteban NV, Yergey AL, Winterer JC, Loriaux DL, Cassorla F: Cortisol production rate in childhood and adolescence. J Pediatr 1990;117:892-896.
11. Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 1993;76:1505-1510.
12. Ten S, New M, Maclaren N: Addisons disease 2001. J Clin Endocrinol Metab 2001;86:2909-2922.
13. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G: Premature mortality in patients with Addisons disease: a population-based study. J Clin Endocrinol Metab 2006;91:4849-4853.
14. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-431.
15. Arlt W, Allolio B: Adrenal insufficiency. Lancet 2003;361:1881-1893.
16. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt W, Allolio B: Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007;92:3912-3922.
17. Lovas K, Husebye ES, Holsten F, Bjorvatn B: Sleep disturbances in patients with Addisons disease. Eur J Endocrinol 2003;148:449-456.
18. Lovas K, Loge JH, Husebye ES: Subjective health status in Norwegian patients with Addisons disease. Clin Endocrinol (Oxf) 2002;56:581-588.
19. Hahner S, Loeffler M, Arlt W, Koschker A, Weismann M, Fassnacht M, Allolio B: Quality of life in chronic adrenal insufficiency results of a crosssectional survey in 256 patients and a populationbased reference cohort. Endocr Soc 2006;P3-730.
20. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S: Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 2009;161:119-130.
21. Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ: Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2006;65:45-50.
22. Lovas K, Husebye ES: Continuous subcutaneous hydrocortisone infusion in Addisons disease. Eur J Endocrinol 2007;157:109-112.
23. Moeller H: Chronopharmacology of hydrocortisone and 9β- fluorhydrocortisone in the treatment for congenital adrenal hyperplasia. Eur J Pediatr 1985; 144:370-373.
24. Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ: Modifiedrelease hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasonesuppressed normal volunteers. Clin Endocrinol (Oxf) 2008;68:130-135.
25. Verma S, Vanryzin C, Sinaii N, Kim MS, Nieman LK, Ravindran S, Calis KA, Arlt W, Ross RJ, Merke DP: A pharmacokinetic and pharmacodynamic study of delayed-and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2010;72:441-447.